<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04683575</url>
  </required_header>
  <id_info>
    <org_study_id>XYJA2020</org_study_id>
    <nct_id>NCT04683575</nct_id>
  </id_info>
  <brief_title>Clinical Study on the Effect of Selenium Yeast Capsule on Prognosis of Differentiated Thyroid Carcinoma</brief_title>
  <official_title>Distribution of Selenium in Patients With Differentiated Thyroid Carcinoma and Effect of Selenium Supplement on Prognosis of Patients With Differentiated Thyroid Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qianfoshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qianfoshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxidative stress is involved in the pathogenesis of thyroid cancer, but the mechanism is not&#xD;
      clear. The thyroid is the organ with the most abundant selenium content, and selenium may be&#xD;
      involved in protecting the gland from the influence of large amounts of H2O2 produced during&#xD;
      thyroid hormone biosynthesis.&#xD;
&#xD;
      Selenium may exert anti-tumor activity through a variety of mechanisms, including inducing&#xD;
      apoptosis and anti-oxidation to change the DNA methylation state of tumor suppressor genes,&#xD;
      cell cycle arrest and stimulation of the immune system, as well as playing an anti-tumor role&#xD;
      through its anti-inflammatory and anti-angiogenesis properties.&#xD;
&#xD;
      The whole blood and thyroid selenium concentrations in patients with thyroid cancer were&#xD;
      lower, and the decreased serum selenium levels were also associated with the high TNM stage&#xD;
      of thyroid cancer.&#xD;
&#xD;
      According to the Nutrition Prevention of Cancer (NPC) trial, selenium yeast supplements with&#xD;
      a daily selenium content of 200 MCG have been shown to reduce the incidence of total cancer,&#xD;
      prostate cancer, colon cancer, and lung cancer, and cancer mortality. The active agent in&#xD;
      selenium yeast supplements is known as selenium methionine (SEMET).&#xD;
&#xD;
      In general, the association between selenium and thyroid cancer is still inconclusive, the&#xD;
      question of whether low selenium is a predisposition factor or a consequence of thyroid&#xD;
      cancer has not been resolved, and the clinical effect of selenium supplementation in&#xD;
      preventing thyroid cancer or improving its prognosis remains to be studied.&#xD;
&#xD;
      The hypothesis is that supplementation with selenium yeast will improve the prognosis of&#xD;
      patients with differentiated alpha-carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 30, 2022</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>experimental group：Selenium yeast treatment group control group：Placebo control group blank control group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>All participants, investigators were blinded to the grouping of the experiment and the intervention.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>recurrence rate</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>metastasis Rate</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Selenium Deficiency</condition>
  <condition>Thyroid Cancer TNM Staging</condition>
  <condition>Recurrence</condition>
  <condition>Metastasis</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with differentiated thyroid carcinoma with low blood selenium are treated with selenium yeast（dosage form：capsule dosage：200μg bid duration: 5 years）.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with differentiated thyroid cancer with low blood selenium are given placebo treatment（dosage form：capsule dosage：200μg bid duration: 5 years）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with differentiated thyroid cancer with low blood selenium are not treated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selenium Yeast</intervention_name>
    <description>oral medication</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral medication</description>
    <arm_group_label>Placebo control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants have signed informed consent forms；&#xD;
&#xD;
          2. Patients with differentiated thyroid carcinoma diagnosed pathologically after thyroid&#xD;
             surgery；&#xD;
&#xD;
          3. Male or female patients aged 18-75 years;&#xD;
&#xD;
          4. Women who are likely to become pregnant must use the appropriate contraceptive method&#xD;
             to avoid pregnancy and minimize the likelihood of conception between the beginning of&#xD;
             the drug intervention study and the 28th day after the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A patient who is pregnant or breastfeeding;&#xD;
&#xD;
          2. Currently, hepatase cytochrome P450 3A4 induction or inhibitor therapy, antiviral&#xD;
             therapy for immunodeficiency diseases (note: hepatase induction or inhibitor:&#xD;
             phenobarbital phenobarbital sodium rifampicin carbamazepine grisoflomycin and&#xD;
             dexamethasone and chloramphenicol allopurinol ketone conazole isoniazid imittidine&#xD;
             phenothiazine);&#xD;
&#xD;
          3. Gastrointestinal surgery that may affect the study of drug absorption;&#xD;
&#xD;
          4. The patient has a history of haemoglobin disease or acute progressive nephropathy or&#xD;
             autoimmune skin disease;&#xD;
&#xD;
          5. A history of substance abuse and alcohol abuse within the last 1 year;&#xD;
&#xD;
          6. There are therapeutic contraindications with selenium yeast capsules as listed in the&#xD;
             instructions;&#xD;
&#xD;
          7. New York Heart Association (NYHA) class III or IV congestive heart failure and/or left&#xD;
             ventricular ejection fraction of 40% with a significant cardiovascular history in the&#xD;
             past 6 months: myocardial infarction coronary angioplasty or bypass surgery valvular&#xD;
             disease or repair of unstable angina transient ischemic attack or cerebrovascular&#xD;
             accident;&#xD;
&#xD;
          8. There are obvious abnormalities in liver function;&#xD;
&#xD;
          9. The patient has significant liver disease acute active hepatitis or chronic active&#xD;
             hepatitis clinical signs or symptoms；&#xD;
&#xD;
         10. Laboratory and physical examination or ECG findings of any clinically significant&#xD;
             abnormality would, in the investigator's judgment, compromise the patient's safety or&#xD;
             prevent successful participation in the clinical study；&#xD;
&#xD;
         11. Patients with severe renal insufficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Liao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qianfoshan Hospital, The First Hospital affiliated of Shandong First Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lin Liao, Doctor</last_name>
    <phone>18354117713</phone>
    <email>liaolin@sdu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First affiliated hospital of Shandong First Medical University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lili Cao, PH.D</last_name>
    </contact>
    <investigator>
      <last_name>Lin Liao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Gheorghiu ML, Badiu C. Selenium involvement in mitochondrial function in thyroid disorders. Hormones (Athens). 2020 Mar;19(1):25-30. doi: 10.1007/s42000-020-00173-2. Epub 2020 Jan 20. Review.</citation>
    <PMID>31960358</PMID>
  </reference>
  <reference>
    <citation>Metere A, Frezzotti F, Graves CE, Vergine M, De Luca A, Pietraforte D, Giacomelli L. A possible role for selenoprotein glutathione peroxidase (GPx1) and thioredoxin reductases (TrxR1) in thyroid cancer: our experience in thyroid surgery. Cancer Cell Int. 2018 Jan 15;18:7. doi: 10.1186/s12935-018-0504-4. eCollection 2018.</citation>
    <PMID>29371830</PMID>
  </reference>
  <reference>
    <citation>Jonklaas J, Danielsen M, Wang H. A pilot study of serum selenium, vitamin D, and thyrotropin concentrations in patients with thyroid cancer. Thyroid. 2013 Sep;23(9):1079-86. doi: 10.1089/thy.2012.0548. Epub 2013 Jul 17.</citation>
    <PMID>23350941</PMID>
  </reference>
  <reference>
    <citation>Moncayo R, Kroiss A, Oberwinkler M, Karakolcu F, Starzinger M, Kapelari K, Talasz H, Moncayo H. The role of selenium, vitamin C, and zinc in benign thyroid diseases and of selenium in malignant thyroid diseases: Low selenium levels are found in subacute and silent thyroiditis and in papillary and follicular carcinoma. BMC Endocr Disord. 2008 Jan 25;8:2. doi: 10.1186/1472-6823-8-2.</citation>
    <PMID>18221503</PMID>
  </reference>
  <reference>
    <citation>Marshall JR, Burk RF, Payne Ondracek R, Hill KE, Perloff M, Davis W, Pili R, George S, Bergan R. Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men. Oncotarget. 2017 Apr 18;8(16):26312-26322. doi: 10.18632/oncotarget.15460.</citation>
    <PMID>28412747</PMID>
  </reference>
  <reference>
    <citation>Barrea L, Gallo M, Ruggeri RM, Giacinto PD, Sesti F, Prinzi N, Adinolfi V, Barucca V, Renzelli V, Muscogiuri G, Colao A, Baldelli R; E.O.L.O. Group. Nutritional status and follicular-derived thyroid cancer: An update. Crit Rev Food Sci Nutr. 2021;61(1):25-59. doi: 10.1080/10408398.2020.1714542. Epub 2020 Jan 30. Review.</citation>
    <PMID>31997660</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 26, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qianfoshan Hospital</investigator_affiliation>
    <investigator_full_name>Lili Cao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Selenium</keyword>
  <keyword>Thyroid Cancer</keyword>
  <keyword>recurrence</keyword>
  <keyword>metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

